BECTON, DICKINSON AND COMPANY
Last · —$188.890.00 (0.00%)live · yahoo · 0s ago
Market cap——
P/E · TTM31.6fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
| Revenue | $20.1B |
|---|---|
| Operating income | $1.9B |
| Net income | $449.0M |
| Free cash flow | $2.7B |
| Operating margin | 9.6% |
| Net margin | 2.2% |
| Return on equity | 1.8% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2025-11-25
- Medical Device Growth
- Advanced Patient Monitoring
- Life Sciences Decline
- China Vbp
- Litigation Exposure
- High Leverage
- Waters Combination
Red flags
- BD had approximately 6,905 outstanding hernia product liability claims at September 30, 2025; settlements are paid over multiple years and future charges could exceed accruals.
- The company reported $1.751 billion of purchase commitments, largely due within one year, while holding only $859 million of cash, equivalents and short-term investments including restricted cash.
- Fiscal 2025 shareholder returns included $1.196 billion of dividends and approximately $1 billion of buybacks despite substantial debt and legal uncertainty.
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
$4.07
Est. revenue
5.1B
Earnings transcripts
Documents
FormReporting forFiledFlags